What happened: India’s patent on semaglutide expired on 20 March, allowing around 50 generic versions to enter the market. These cheaper alternatives could make weight-loss medication more accessible worldwide.
Why it matters:
- More affordable drugs could help tackle obesity on a global scale.
- Patients in low- and middle-income countries may gain better access to effective treatments.
MNN Take: The end of India’s semaglutide patent means increased competition and lower prices, potentially expanding treatment options for obesity beyond wealthier nations.
Sources: BBC World